EP Patent

EP3702374A1 — Manufacturing process for cyclodextrin derivatives

Assigned to Cydex Pharmaceuticals Inc · Expires 2020-09-02 · 6y expired

What this patent protects

A process and equipment assembly for reacting a substituent precursor with a cyclodextrin starting material to provide a raw product comprising a cyclodextrin derivative and 1% or less of an initial amount of the substituent precursor is provided. The process of the present inven…

USPTO Abstract

A process and equipment assembly for reacting a substituent precursor with a cyclodextrin starting material to provide a raw product comprising a cyclodextrin derivative and 1% or less of an initial amount of the substituent precursor is provided. The process of the present invention provides cyclodextrin derivatives in substantially shorter time and with fewer side products than previous processes that utilize substantially the same starting materials.

Drugs covered by this patent

Patent Metadata

Patent number
EP3702374A1
Jurisdiction
EP
Classification
Expires
2020-09-02
Drug substance claim
No
Drug product claim
No
Assignee
Cydex Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.